Pancreatic amylin plays an important role in the control of nutrient fluxes and is an established therapy in human diabetes as it reduces post-prandial glucagon secretion and slows gastric emptying. Given the similar pathophysiology of human type-2 and feline diabetes mellitus, we investigated whether amylin reduces plasma glucagon levels in cats. Healthy cats were tested using an intravenous arginine stimulation test (IVAST), a meal response test with the test meal comprising 50% of average daily food intake, and an IV glucose tolerance test (IVGTT). Non-amyloidogenic rat amylin injected 5min before the respective stimulus significantly reduced plasma glucagon levels under all test situations. In the IVAST and IVGTT, cats treated with amylin also had lower plasma insulin concentrations. It was concluded that amylin does reduce plasma glucagon levels in cats, a feature that has treatment potential in diabetic animals as co-administration of amylin would reduce the insulin requirement to control glycaemia. 
Introduction

40
Diabetes mellitus (DM) is a common endocrinopathy in cats. Its prevalence has risen 41 over the last 30 years possibly reflecting the higher prevalence of obesity in this species. Cats are 42 an interesting model of DM in that they spontaneously develop a form of the disease similar to 43 human type-2 DM (T2DM) (Lutz and Rand, 1995; Cefalu, 2006; Henson and O'Brien, 2006) .
44
Diabetic cats are often middle aged and, similar to human T2DM, obesity with concurrent insulin 45 resistance is a major risk factor, and impaired beta-cell function is present. The most striking 46 histological similarity between human T2DM and the disease in cats is the amylin-derived islet amyloidosis that is found in > 80% of diabetic cats (Lutz and Rand, 1995) . Primates and felines 48 develop islet amyloidosis due to the amyloidogenic amino acid sequence of amylin while rodents 49 do not spontaneously develop T2DM-like disease as their amylin is non-amyloidogenic 50 (Westermark et al., 1990; Johnson et al., 1992) .
52
Amylin is a normal secretory product of pancreatic beta-cells, co-synthesised and co-53 secreted with insulin in response to appropriate stimuli (Lutz and Rand, 1996; Young, 2005a) so 54 that plasma insulin and amylin levels usually parallel each other. Early-stage or mild feline DM 55 may be characterised by compensatory hyperinsulinaemia and absolute or relative 56 hyperamylinaemia (O'Brien et al., 1991; Lutz and Rand, 1996) . In such circumstances 57 hyperamylinaemia may favour the deposition of amylin as pancreatic amyloid. Frequently 58 however, clinical cases of feline DM are presented to veterinarians in more severe or late-stage 59 disease by which time progressive beta-cell failure has resulted in overt hypoinsulinaemia and 60 hypoamylinaemia (Johnson et al., 1989; Ludvik et al., 1991) . secretion of glucagon, over-eating and accelerated gastric emptying. Amylin reduces the excessive post-66 prandial hyperglucagonaemia observed in DM (Fineman et al., 2002) and normalises gastric emptying in 67 human diabetics treated with pramlintide, a non-amyloidogenic amylin analogue (Thompson et al., 68 1998; Weyer et al., 2001; Fineman et al., 2002; Ratner et al., 2002; Vella et al., 2002; Hollander et al., 69 2003 Hollander et al., 69 , 2004 Maggs et al., 2004) .
71
Hyperglucagonaemia is also a feature of diabetic cats (Tschuor et al., 2006) , but it remains 72 unknown if this is due to the lack of amylin. Given the similar pathophysiology of human T2DM and 73 feline diabetes, and given that human diabetics are successfully treated with a combination of amylin 74 and insulin, it seems pertinent to study the effect of amylin on glucagon secretion in cats. In this study 75 we investigate the effect of amylin injection on plasma glucagon levels in healthy cats under three test 76 conditions: an intravenous (IV) arginine stimulation test (IVAST); a meal response test (MRT); and an
77
IV glucose tolerance test (IVGTT). Plasma glucagon levels increased in response to arginine injection 78 and to feeding but were reduced following IV glucose administration. In our study we used rat amylin 79 because of its non-amyloidogenic properties (Westermark et al., 1990; Johnson et al., 1992) and 80 assessed if it reduced plasma glucagon concentrations under these test conditions in healthy cats. The 81 doses of amylin used (5 or 10 µg/kg) were based on effective doses previously used in rats and humans 82 (Young et al., 1996; Hollander et al., 2003; Lutz, 2005) .
Materials and Methods
84
The procedures were carried out on 12 male domestic short-hair cats (Harlan Sprague old at the time of study. Their average bodyweight was 4.9 ± 0.4 kg. Products) was inserted using the Seldinger technique (Seldinger, 1953) and sutured to the skin on 99 the day prior to testing. Cats were sedated with ketamine (Ketaminol, Veterinaria) at a dose of 5-100 7 mg/kg intramuscular (IM) and midazolam (Dormicum, Roche) at 0.2 mg/kg (IM), followed by 101 IV propofol (Fresenius Kabi) at 6-7 mg/kg to anaesthetise.
102
Pharmacokinetic of rat amylin in cats
103
We determined the pharmacokinetics of rat amylin in four cats in a pilot experiment. Rat 104 amylin (Amylin Pharmaceuticals Inc.) was used as, in contrast to cat amylin, it is non-amyloidogenic. The dose of amylin used (5 µg/kg dissolved in 0.1 mL/kg saline) was based on 106 that effective in rats and humans (Young et al., 1996; Hollander et al., 2003; Lutz, 2005) The IVAST was used to investigate the effect of amylin on arginine induced glucagon 113 secretion. Six cats per group were fasted overnight for 12 h before testing. After taking a 2 mL concentrations) and was centrifuged immediately. EDTA-plasma was treated as described above.
122
Meal response test
123
Six cats per group were fasted for 24 h before the MRT which was carried out at the 124 onset of the light period. After taking a 2 mL basal blood sample, amylin (5 µg/kg) or saline 125 solution (control treatment, 0.1 mL/kg) were injected SC and 5 min later, the test meal 126 comprising 50% of the average daily food intake was offered. All food was consumed within 10
Intravenous glucose tolerance test
132
Six cats per group were fasted for 12h overnight before the IVGTT. After taking a 2 Rand, 1996). Volume replacement was achieved by injecting 0.9% saline solution and blood 138 samples were treated as described above.
139
Biochemical analysis
140
The blood glucose concentration was measured using an automated photometric test 141 and the hexokinase method (Cobas Integra Analyser, Roche). Amylin was measured by an in-142 house radioimmunoassay (RIA). In brief, antibodies directed against rat amylin (T-486-6; rabbit 143 anti-rat-amylin antibodies; kindly provided by T. Pieber, Graz, Austria) were dissolved in 144 phosphate buffer containing Na 2 HPO 4 (50 mMol/L, pH 7.2), aprotinine (1%), EDTA (0.25%),
145
Triton X 100 (0.2%), fish gelatine (0.1%) and sodium azide (0.02%) (all Sigma). Antibodies 146 were used at a final dilution of 1:50,000 and rat amylin (Peninsula Laboratories) was used as a 147 standard. Samples and standards were incubated for 72 h at 4 °C. Radiolabeled amylin ( 125 I-148 amylin, 9,000-10,000 cpm, Amersham) was added and samples were incubated for 96 h at 4 °C.
149
Goat anti-rabbit antibodies (Sigma) and polyethylene glycol were added to separate bound from unbound amylin. Radioactivity was counted by gamma-counter (GAMMAmatic 1, Kontron 151 Analytical).
153
Insulin and glucagon were measured using commercial RIA kits: insulin using the 154 Linco Porcine Insulin RIA Kit (# PI-12K, Millipore); and glucagon using the ICN Biomedicals 155 kit (# 07152101, MP Biomedicals Europe), both of which were validated prior to use. For the 156 insulin assay, inter-and intra-assay coefficients of variation were 7.0 % and 6.5% respectively 157 and the sensitivity was approximately 0.3 µIU/mL (2 pMol/L). Observed-to-expected ratios for 158 serial dilutions (12.5-100%) ranged from 103.2-106.4% (Zini et al., 2008) . For the glucagon 159 assay, inter-and intra-assay coefficients of variation were 8.2 % and 7.5% respectively and the 160 sensitivity was approximately 50 pg/mL.
161
Statistical analysis
162
The area under the curve (AUC) was calculated above the baseline of each individual 163 animal using GraphPad Prism software (GraphPad Inc.) and these values were used to compute 164 the average AUC. All values are given as mean ± standard error of the mean (SEM). The 165 experiments were performed using cross-over design with at least 4 weeks between trials.
166
Statistical tests applied included paired Student's t-tests or repeated measures ANOVA, as 167 appropriate and P values < 0.05 were considered significant. administration, rat amylin was largely cleared from the circulation (Fig. 1) .
181
Intravenous arginine stimulation test
182
Arginine injection resulted in a slight increase in plasma glucose levels in all groups of 183 approximately 1.5 mMol/L. By 30 min after injection, plasma glucose levels had returned to 184 baseline values. Amylin had no effect on the plasma glucose concentration at any time-point 185 ( Fig. 2A) . Plasma insulin increased approximately 6-fold following arginine administration 186 (from 7.1 µIU/mL at t = 0 to 45.4 ± 10.2 µIU/mL at t = 7 min). Interestingly, the arginine-187 induced increase in the plasma insulin concentration was lower in cats previously given amylin 188 (Fig. 2B) . Arginine administration also increased plasma glucagon levels and this increase was 189 reduced following amylin administration (Fig. 2C) . Amylin treatment reduced the total glucagon 190 secretory response relative to that of control cats, as indicated by the AUC within the first 15 min 191 of its administration (Fig. 2D ). Both doses of amylin produced similar effects.
Meal response test
194
Ingestion of the meal did not result in post-prandial hyperglycaemia, irrespective of 195 treatment so that the plasma glucose concentration was unaffected by amylin administration (Fig.   196   3A) . The post-prandial plasma insulin concentration increased approximately 3-fold relative to 197 fasting levels peaking at 24.3 ± 5.5 µIU/mL immediately when the meal ended and had returned (Fig. 3B) . Interestingly, the total insulin output, as indicated by the AUC, was significantly lower in cats 209 that had been given amylin (Fig. 4A) . Glucose administration resulted in a time-dependent 210 decrease in plasma glucagon concentrations which was more pronounced in amylin-treated cats 211 relative to controls (Fig. 4B ). Both doses of amylin produced similar effects. Importantly, the increase in plasma glucagon was significantly reduced by amylin. This was 230 paralleled by a reduction in overall insulin secretion relative to the controls. A limitation of our study was that, given the effects of amylin on plasma glucagon levels 254 were small, they may not be of great clinical significance. The effects of amylin were not dose-255 dependent at the two doses we tested and also it must be noted that the cats used in our study 256 were young, healthy and of normal body weight. However, even in such animals, with fully 257 functional endocrine systems, the effect of amylin on the plasma glucagon concentration was 258 found and we suggest this response may be much more pronounced in diabetic cats. Although 259 amylin secretion may be increased initially in diabetics, the later stages of the disease are characterised by marked hypoamylinaemia (Lutz and Rand, 1996; Young, 2005a,c) , so that any 261 effect of exogenous amylin is likely to be much more pronounced in diabetic cats.
263
Although the effects of amylin were relatively short-term and occurred at slightly 264 different time-points in the three tests, we do not consider that this precludes the use of amylin as 265 an adjunct treatment in diabetes. The current experiment was a 'proof-of-concept' study of the 266 effect of amylin in the cat. The amylin analogue pramlintide, with similar pharmacodynamics to 267 the amylin preparation used in our study (Young et al., 1996) , has been used to successfully treat were the relatively small number of cats used and the fact that plasma glucagon concentrations 271 and not direct secretion were measured. Given that amylin is unlikely to influence renal glucagon 272 clearance, we suggest that plasma glucagon concentrations reliably reflect pancreatic alpha cell 273 secretion.
274
Conclusions
275
This study provides the first evidence that amylin lowers plasma glucagon concentrations 276 in the cat. Amylin may therefore have therapeutic potential in diabetic cats, as it has in humans 277 given that hyperglucagonaemia is a feature of the disease in both species (Tschuor et al., 2006) .
278
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